Clinical Trial Update: Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma [Phase 1]

View source ↗

Summary

Phase I trial evaluating arsenic trioxide in combination with stereotactic radiotherapy for recurrent malignant glioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Arsenic Trioxide (Trisenox) (arsenic trioxide)

Snippet

Sponsor: Stanford University | Conditions: Brain Cancer | Phase 1 | Status: COMPLETED